Following a full submission
AWMSG advice |
|||
| Status: Superseded | |||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED MARCH 2018. Refer to TA516: Cabozantinib for treating medullary thyroid cancer for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
|||
|
|||
Medicine details |
|||
| Medicine name | cabozantinib (Cometriq®) | ||
| Formulation | 20 mg and 80 mg capsule | ||
| Reference number | 577 | ||
| Indication | Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. For patients in whom Rearranged during Transfection (RET) mutation status is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision |
||
| Company | Swedish Orphan Biovitrum Ltd / TMC Pharma Services Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Full | ||
| Status | Superseded | ||
| Advice number | 4014 | ||
| NMG meeting date | 19/11/2014 | ||
| AWMSG meeting date | 17/12/2014 | ||
| Ratification by Welsh Government | 28/01/2015 | ||
| Date of issue | 29/01/2015 | ||
| NICE guidance | |||